Cigna's partnership with $LLY (+1,75 %) and $NOVO B (-1,83 %) to cap co-payments at $200 for Zepbound and Wegovy (i.e. $400 cheaper) has 0 significance for $HIMS (-2,98 %) . Since Hims is not in the insurance business and others are willing to sell it for $0!
